Marketing-authorisation holder
Eumedica Pharmaceuticals GmbH
24 medicines in 3 countries, as authorisation holder and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder
24 medicines in 3 countries, as authorisation holder and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
24 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BACTRIMCompressa | Trimethoprim, Sulfametossazolo | Italy | Authorised | |
| BACTRIM PERFUSIONEConcentrato per soluzione per infusione | Trimethoprim, Sulfametossazolo | Italy | Authorised | |
| BACTRIMELSospensione orale | Trimethoprim, Sulfametossazolo | Italy | Authorised | |
| Bactrimel, concentraat voor oplossing voor intraveneuze infusie 96 mg/mlConcentraat voor oplossing voor infusie | Sulfamethoxazole, Trimethoprim | Netherlands | Authorised | 1978 |
| BUPREX 0,2 mg COMPRIMIDOS SUBLINGUALES0,216 mg · Comprimido sublingual | Buprenorphine | Spain | Marketed | 1985 |
| CILOTEM 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION1 g · Polvo para solución inyectable y para perfusión | Temocillin | Spain | Authorised | 2026 |
| CILOTEM 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION2 g · Polvo para solución inyectable y para perfusión | Temocillin | Spain | Authorised | 2026 |
| Dipiperon 40 mg/ml, druppelsDruppels voor oraal gebruik, oplossing | Pipamperone | Netherlands | Authorised | 1983 |
| Dipiperon 40 mg, tablettenTablet | Pipamperone | Netherlands | Authorised | 1968 |
| Imap 2 mg/ml, suspensie voor injectieSuspensie voor injectie | Fluspirilene | Netherlands | Authorised | 1971 |
| Impromen 2 mg/ml, druppelsDruppels voor oraal gebruik, oplossing | Bromperidol | Netherlands | Authorised | 1980 |
| Impromen decanoas 50 mg/ml, oplossing voor injectieOplossing voor injectie | Bromperidol | Netherlands | Authorised | 1983 |
| Negaban 1 g poeder voor oplossing voor injectie/infusiePoeder voor oplossing voor injectie of infusie | Temocillin | Netherlands | Authorised | 2026 |
| Negaban 2 g poeder voor oplossing voor injectie/infusiePoeder voor oplossing voor injectie of infusie | Temocillin | Netherlands | Authorised | 2026 |
| ORAPCompressa | Pimozide | Italy | Authorised | |
| ORAP 1 mg COMPRIMIDOS1 mg · Comprimido | Pimozide | Spain | Marketed | 1971 |
| ORAP FUERTE 4 mg COMPRIMIDOS4 mg · Comprimido | Pimozide | Spain | Marketed | 1971 |
| Orap tabletten 1 mg, tablettenTablet | Pimozide | Netherlands | Authorised | 1971 |
| Orap tabletten 4 mg, tablettenTablet | Pimozide | Netherlands | Authorised | 1971 |
| TEMGESICCompressa sublinguale | Buprenorphine | Italy | Authorised | |
| Temgesic 0,2 mg tabletten voor sublinguaal gebruikTablet voor sublinguaal gebruik | Buprenorphine | Netherlands | Authorised | 1989 |
| Temgesic 0,3 mg/ml oplossing voor injectieOplossing voor injectie | Buprenorphine | Netherlands | Authorised | 1981 |
| BUPREX 0,3 mg SOLUCION INYECTABLE0,324 mg · Solución inyectable | Buprenorphine | Spain | Suspended | 1984 |
| SOMATOSTATINA EUMEDICA 250 mcg 1 VIAL POLVO LIOFILIZADO + 1 AMPOLLA DE DISOLVENTE DE 1 ml250 µg · Polvo y disolvente para solución para perfusión | Somatostatin | Spain | Withdrawn | 1993 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Netherlands | 12 | 12 | 0 | CompaniesAll medicines |
| Spain | 7 | 5 | 2 | CompaniesAll medicines |
| Italy | 5 | 5 | 0 | CompaniesAll medicines |
Also in the registers of United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Report an error or request removalCorrections from the company itself are welcome.